Amgen to acquire Micromet
26 January 2012 | By Amgen
Amgen and Micromet, Inc. announced that the companies have entered into a definitive merger agreement...
List view / Grid view
26 January 2012 | By Amgen
Amgen and Micromet, Inc. announced that the companies have entered into a definitive merger agreement...
29 December 2011 | By Amgen
FDA has invited Amgen to participate in a meeting of the ODAC on Feb. 8, 2012 to discuss the sBLA for XGEVA® (denosumab)...
19 December 2011 | By Amgen
Kevin W. Sharer has announced his plan to retire from the Company at the end of 2012...
15 December 2011 | By Amgen
Additional key Nplate (Romiplostim) data also presented at American Society of Hematology annual meeting...
15 November 2011 | By Amgen
The EC has approved a variation to the marketing authorization for Vectibix®...
5 November 2011 | By Pfizer
PRESERVE trial results...
5 November 2011 | By Amgen
Positive data of the pivotal Phase 3 fracture trial...
19 October 2011 | By Amgen
Amgen appoints Anthony Hooper as Executive VP, Global Commercial Operations...
13 October 2011 | By Amgen
Amgen announced that its Board of Directors has appointed Robert A. Bradway to the Company's Board...
22 August 2011 | By Amgen
The FDA will target a PDUFA action date of April 26, 2012 for the sBLA...
15 July 2011 | By Amgen
Amgen announced that the U.S. District Court in Pennsylvania has entered final judgment and a permanent injunction against TEVA...
15 July 2011 | By Amgen
The European Commission has granted marketing authorization for XGEVA® (denosumab)...
5 July 2011 | By Amgen
Amgen and UCB announced that they are collaborating with the NASA Ames Research Center to conduct a preclinical test...
27 June 2011 | By Amgen
Amgen announced the submission of a supplemental Biologics License Application to the U.S. FDA to expand the indication for XGEVA® (denosumab)...
20 May 2011 | By Amgen
Amgen announced that the CHMP of the EMA has recommended a positive opinion for the marketing authorization of XGEVA™ (denosumab)...